Company intelligence / Profile preview

Carrington Laboratories

Ownership: Private
Employees: ~249
Development stage: Other

Overview

Carrington developed proprietary carbohydrate-based technologies including GelSite® for controlled release and mucosal drug/vaccine delivery. Its DelSite subsidiary advanced a nasal powder vaccine platform into Phase I trials with H5N1 antigen. The company also commercialized Manapol® (nutraceutical) and Hydrapol™ (cosmetic) raw materials derived from Aloe vera L., with claims of immune enhancement. Some products achieved CE mark approval.

Therapeutic areas: GastroenterologyDermatologyInfectious Diseases
Modalities: Small moleculePeptidesProtein-based drugscomplex carbohydrates and polysaccharide-based delivery systems
Industry: Biotech

Drug pipeline

9 assets

acemannan

8 more assets in the full pipeline.

Partnerships

ElSohly Laboratories (anticancer drug formulation using GelSite® polymer)

Beyond the preview

Go deeper on Carrington Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carrington Laboratories.